Abstract 323P
Background
An immune checkpoint inhibitor that targets programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has recently been discovered, and it demonstrates superior treatment efficacy and improves prognosis over existing chemotherapeutic agents in non-small cell lung cancer. Several studies have demonstrated correlations between computed tomography (CT) imaging features and PD-L1 expression in lung adenocarcinoma (ADC). However, there have been few studies on the association between lung squamous cell carcinoma (SCC) and CT findings. Thus, we aimed to identify the associations between CT findings and PD-L1 expression in SCC and to develop models to predict the expression of PD-L1 in lung SCC using CT.
Methods
This retrospective study included 99 patients diagnosed with SCC and pretreatment CT images and PD-L1 expression assay results. We performed CT feature analysis of the tumors using pretreatment CT images. We then constructed multiple logistic regression models to predict PD-L1 positivity in the total patient group and in 41 advanced-stage (≥ stage IIIB) patients. To identify predictive efficiency, areas under the receiver operating characteristic curves (AUCs) of each model were calculated.
Results
Among the 99 patients, 68 (68.7%) were PD-L1-positive and among the 41 advanced patients, 30 (73.2%) were PD-L1-positive. For the total patient group, the AUC of the ‘total significant features model’ (tumor stage, primary tumor size, pleural nodularity and lung metastasis) was 0.637, and that of the ‘selected feature model’ (pleural nodularity) was 0.556. For advanced-stage patients, the AUC of the selected feature model (primary tumor size, central distribution, pleural nodularity, and pulmonary oligometastases) was 0.882. Among these factors, the presence of pleural nodularity and pulmonary oligometastases had high odds ratios (4.11 and 9.60, respectively).
Conclusions
Our model was able to predict PD-L1 expression in patients with advanced-stage SCC of the lung, and the presence of pleural nodularity and pulmonary oligometastases were notable predictive CT features of PD-L1. A predictive model based on CT features may facilitate non-invasive assessment of PD-L1 expression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by a VHS Medical Center Research Grant, Republic of Korea (grant number: VHSMC 21007).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
374P - NX-019, a brain penetrant, mutation selective EGFR inhibitor with broad mutant EGFR activity
Presenter: Keith Wilson
Session: Poster viewing 05.
375P - Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): A phase II, prospective study
Presenter: Jiayan Chen
Session: Poster viewing 05.
377P - Aumolertinib as second-line therapy in T790M-positive or-negative patients with EGFR-mutated non-small cell lung cancer (NSCLC): A retrospective study
Presenter: Hongying Lv
Session: Poster viewing 05.
378P - Could the model of EGFR-TKIs plus antiangiogenesis as first-line treatments in patients with EGFR-mutated non-small cell lung cancer take a step further: A updated meta-analysis
Presenter: Yuexiao Qi
Session: Poster viewing 05.
380P - Survival outcome and cost-effectiveness of tyrosine kinase inhibitor in EGFR sensitive mutation advanced-stage NSCLC in Thammasat university hospital
Presenter: Chayanid Rungtivasuwan
Session: Poster viewing 05.
381P - Real-world experience of treatment with afatinib in advanced non-small cell lung cancer (NSCLC) in Vietnam
Presenter: Hiep Dong
Session: Poster viewing 05.
382P - Real-world data on treatment outcome of ALK positive non-small cell lung cancer from an Indian multi-centric cancer registry
Presenter: Soumya Surath Panda
Session: Poster viewing 05.
383P - Treatment outcomes with BRAF inhibitors with or without MEK inhibitors in advanced non-small cell lung cancer with positive BRAF mutation: A systematic review
Presenter: Animesh Saha
Session: Poster viewing 05.
384P - Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
Presenter: Hiroaki Akamatsu
Session: Poster viewing 05.